钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病贫血的有益作用——一项真实世界研究
该回顾性队列研究基于Clalit健康服务数据库,纳入22896例2型糖尿病患者,其中11448例接受SGLT2抑制剂治疗,倾向评分匹配等量DPP4抑制剂对照。结果显示SGLT2抑制剂组贫血风险显著更低(HR=0.6,95%CI 0.58-0.63),贫血相关住院风险(HR=0.67,95%CI 0.58-0.77)及贫血治疗需求(HR=0.84,95%CI 0.78-0.92,P<.001)均更低。
要点
- SGLT2抑制剂组贫血风险显著低于DPP4抑制剂组(HR=0.6,95%CI 0.58-0.63)。
- SGLT2抑制剂组贫血相关住院风险更低(HR=0.67,95%CI 0.58-0.77)。
- SGLT2抑制剂组贫血治疗需求更低(HR=0.84,95%CI 0.78-0.92,P<.001)。
核心结论
- 在糖尿病患者中,与DPP4抑制剂治疗相比,SGLT2抑制剂显示出更低的贫血患病率和更低的贫血相关住院风险。
研究设计与样本
- 回顾性队列研究,数据来源于Clalit健康服务数据库,2016年1月1日至2021年12月31日期间识别接受SGLT2抑制剂治疗的2型糖尿病患者,并使用倾向评分匹配等量接受DPP4抑制剂治疗的对照组。
主要发现
- 共纳入22896例患者,其中11448例接受SGLT2抑制剂,等量患者接受DPP4抑制剂。
- 与DPP4抑制剂组相比,SGLT2抑制剂组贫血风险显著更低(HR=0.6,95%CI 0.58-0.63)。
- SGLT2抑制剂组贫血相关住院风险显著更低(HR=0.67,95%CI 0.58-0.77)。
- SGLT2抑制剂组贫血治疗需求更低(HR=0.84,95%CI 0.78-0.92,P<.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the impact of sodium-glucose cotransporter 2 (SGLT2) inhibitors on the incidence, complications, and therapeutic demands of anemia in patients with diabetes utilizing real-world data, compared to treatment with dipeptidyl peptidase 4 (DPP4) inhibitors. METHODS: In this retrospective cohort study, the dataset was sourced from the data repositories of Clalit Health Services. From January 1, 2016, through December 31, 2021, we identified patients with type 2 diabetes who received treatment with SGLT2 inhibitors and compared them with a matched control group treated with DPP4 inhibitors using propensity score. The primary endpoint was the prevalence of anemia. RESULTS: A total of 22 896 patients were included in this study, with 11 448 individuals administered SGLT2 inhibitors, and an equal number treated with DPP4 inhibitors. We found a significant lower hazard of anemia among patients treated with SGLT2 inhibitors (HR = 0.6, 95% CI 0.58-0.63) compared to those treated with DPP4 inhibitors. Moreover, the risk of hospitalizations attributed to anemia was significantly lower with SGLT2 inhibitors (HR 0.67, 95% CI 0.58-0.77). SGLT2 inhibitors were associated with a lower necessity for anemia treatment (HR 0.84, 95% CI 0.78-0.92, P < .001). CONCLUSION: SGLT2 inhibitors demonstrated a lower prevalence of anemia and a lower risk of hospitalizations attributed to anemia when compared to treatment with DPP4 inhibitors in patients with diabetes.
引用
- Steinmetz T, Goldman S, Kagan KBT, et al. The Beneficial Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Anemia in Type 2 Diabetes-A Real-World Study. J Clin Endocrinol Metab. 2025. PMID: 40120086. doi:10.1210/clinem/dgaf184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。